Fara Brasó-Maristany

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Post-doctoral researcher (R2A)

fbraso@recerca.clinic.cat 0000-0001-5440-9643

Publicacions destacades

Gene expression profiles of breast cancer metastasis according to organ site

Autors:
Brasó-Maristany, F; Chic, N; Martínez-Sáez, O; Mallafré-Larrosa, M; Schettini, F;

(...)

Pascual, T; Ciruelos, E; Salinas, B; Tolosa, P; Carcelero, E.

Referència: Molecular Oncology 2022.
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

Autors:
Braso-Maristany, F; Chic, N; Martinez, D; González-Farre, B; Sanfeliu, E;

(...)

Soy, D; Sanchez, M; Jares, P; Peg, V; Saura, C.

Referència: Frontiers In Oncology 2021.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Autors:
Chic, N; Schettini, F; Brasó-Maristany, F; Sanfeliu, E; Adamo, B;

(...)

Bellet, M; Cortés, J; Soberino, J; Carey, LA; Perou, CM.

Referència: Ebiomedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Autors:
Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

(...)

Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

Referència: Journal Of Clinical Oncology 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Autors:
Martínez-Sáez, O; Pascual, T; Brasó-Maristany, F; Chic, N; González-Farré, B;

(...)

Prat, A; Rodríguez, A; Martínez, A; Faull, I; Odegaard, JI.

Referència: Npj Breast Cancer 2021.
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Autors:
Prat, Aleix; Tsai, Yi-Hsuan; Pascual, Tomas; Pare, Laia; Adamo, Barbara;

(...)

Brase, Jan Christoph; Rodrik-Outmezguine, Vanessa; Johnston, Stephen; Ciruelos, Eva; Parker, Joel S.

Referència: Clinical Cancer Research 2020.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Autors:
Griguolo, G; Giarratano, T; Dieci, MV; Conte, P; Guarneri, V;

(...)

Christgen, M; Kreipe, H; Monge-Escartín, I; Soy, D; Harbeck, N.

Referència: Cancers 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Autors:
Brasó-Maristany, F; Griguolo, G; Pascual, T; Vidal, M; Adamo, B;

(...)

Manso, L; Alarcón, J; Martínez, E; Gregorio, S; Gomis, RR.

Referència: Nature Communications 2020.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Autors:
Prat, A; Pascual, T; Paré, L; Adamo, B; Brasó-Maristany, F;

(...)

Parker, JS; Dieci, MV; Griguolo, G; Conte, P; Guarneri, V.

Referència: Journal Of The National Cancer Institute 2020.
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

Autors:
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J;

(...)

Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN .

Referència: Nature Medicine 2016.

Projectes destacats

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Investigador/a principal: Fara Brasó Maristany

Finançador: Fundación Científica Asociación Española Contra el Cáncer (AECC).

Codi: INVES21943BRAS

Durada: 01/12/2021 - 30/11/2024
Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Investigador/a principal: Aleix Prat

Finançador: Asociación Española Contra el Cáncer (AECC) ; Fundación Científica Asociación Española Contra el Cáncer (AECC).

Codi: Ayuda Postdoctoral AECC 2017

Durada: 01/11/2017 - 31/10/2021

Web: https://www.aecc.es/es/investigacion/proyectos-aecc/estudio-mecanismos-sensibilidad-resistencia-doble-bloqueo-her2-combinaciones-con-enzalutamida-o-palbociclib-modelos-preclinicos-cancer-mama-her2

Fara Brasó-Maristany

Grup de recerca

Publicacions destacades

Projectes destacats

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Subscriu-te a la Newsletter del Clínic